Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.68 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.41 |
| ▸ | CCKAR | P32238 | 5/20 | 0.41 |
| ▸ | CCKBR | P32239 | 5/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16638275 | 1.00 | GLP1R (0.68) | GLP1RFOLH1NOD1CCKARCCKBR | |
| SCHEMBL12118666 | 1.00 | GLP1R (0.68) | GLP1RFOLH1NOD1CCKARCCKBR | |
| SCHEMBL16711028 | 1.00 | GLP1R (0.68) | GLP1RFOLH1NOD1CCKARCCKBR | |
| SCHEMBL16638310 | 1.00 | GLP1R (0.68) | GLP1RFOLH1NOD1CCKARCCKBR | |
| SCHEMBL16947835 | 1.00 | GLP1R (0.68) | GLP1RFOLH1NOD1CCKARCCKBR | |
| SCHEMBL12118710 | 1.00 | GLP1R (0.68) | GLP1RFOLH1NOD1CCKARCCKBR | |
| SCHEMBL17127177 | 0.99 | GLP1R (0.67) | GLP1RFOLH1NOD1CCKARCCKBR | |
| SCHEMBL15355763 | 0.99 | GLP1R (0.67) | GLP1RFOLH1NOD1CCKARCCKBR | |
| SCHEMBL17127178 | 0.99 | GLP1R (0.67) | GLP1RFOLH1NOD1CCKARCCKBR | |
| SCHEMBL20900397 | 0.94 | GLP1R (0.70) | GLP1RFOLH1NOD1CCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230126068-A1 | Insulin Derivative | GAN & LEE PHARMACEUTICALS CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20150274801-A1 | ACYLATED GLUCAGON ANALOGUES | NOVO NORDISK AS (DK) | 2015-10-01 | — | — | US | disclosed |
| US-9006178-B2 | Double-acylated GLP-1 derivatives with a linker | NOVO NORDISK A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| US-20110275559-A1 | Long-Acting Y2 and/or Y4 Receptor Agonists | NOVO NORDISK A/S (DK) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126068-A1 | Insulin Derivative | IAPP, GLP1R, INSR | GLP1R 2/4885FOLH1 3068/4885NOD1 909/4885 |
| US-20150274801-A1 | ACYLATED GLUCAGON ANALOGUES | GLP1R, GCG, IAPP | GLP1R 1/4885FOLH1 352/4885NOD1 2294/4885 |
| US-20110275559-A1 | Long-Acting Y2 and/or Y4 Receptor Agonists | NPY4R, NPY1R, NPY2R | GLP1R 6/4885FOLH1 2539/4885NOD1 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.